Live Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection.
Natasha N PettitKristy M ShaeerElias B ChahinePublished in: The Annals of pharmacotherapy (2024)
Live biotherapeutic products provide a safe and effective option for the prevention of rCDI and represent an improvement over conventional FMT. Additional studies are needed to further determine their place in therapy relative to bezlotoxumab and in the setting of immunosuppression and inflammatory bowel disease.